NCT06727422View on ClinicalTrials.gov

Efficacy of Rifaximin with NAC in IBS-D

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

225

Participants

Timeline

Start Date

April 1, 2025

Primary Completion Date

April 1, 2026

Study Completion Date

January 1, 2027

Conditions
IBS (Irritable Bowel Syndrome)IBS-D (diarrhea-predominant)
Interventions
DRUG

rifaximin 66mg + N-acetylcysteine 560mg three times daily

RNIB21 containing rifaximin 66mg + N-acetylcysteine 560mg three times daily

DRUG

RNIB21 containing rifaximin 132mg + N-acetylcysteine 560mg three times daily

RNIB21 containing rifaximin 132mg + N-acetylcysteine 560mg three times daily

DRUG

Placebo

placebo three times daily

All Listed Sponsors
lead

Mark Pimentel, MD

OTHER